Early Immune Responses to Vaccination - A Substudy to HVTN 205
NCT00908323
Completed
HVTN 908 is a sub study of the HIV vaccine trial, HVTN 205. The purpose of this sub study is to better understand how a person's immune system responds to vaccines, particularly HIV vaccines. More specifically, researchers will determine whether early responses in the immune system help predict strong and long-lasting immunity.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama Vaccine CRS, Birmingham, Alabama +2 locations
Conditions: HIV Infections
Register for Updates
Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins
NCT01054872
Completed
The purpose of this study is to examine the role of genetics in determining the immune response to an HIV vaccine in pairs of HIV-uninfected twins.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts +1 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
NCT01479296
Completed
The purpose of this study is to evaluate the immune response to the Vaccine Research Center (VRC) rAd5 HIV vaccine when the vaccine components are administered in three different ways, in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Bridge HIV CRS, San Francisco, California +7 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
NCT01571960
Completed
This study will test the safety and immune responses of a prime-boost regimen of two HIV vaccines- a DNA vaccine followed by a modified vaccinia Ankara (MVA) vaccine- in healthy, HIV-uninfected, vaccinia-naive adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama CRS, Birmingham, Alabama +3 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults
NCT01578889
Completed
Some vaccines may work better when given together with another substance known as an adjuvant or when given with an experimental procedure called electroporation (EP). EP is a method where an electric pulse is administered to the same muscle where the vaccine injection is given. The addition of the adjuvant to the vaccine and the delivery with EP may increase a person's immune response to the vaccine. Combination approaches such as a DNA vaccine followed by live vector boost may also increase a... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Columbia P&S CRS, New York, New York +4 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults
NCT01783977
Completed
NOTE: This study has stopped enrolling new participants, and all study vaccinations for currently enrolled participants have been stopped. Currently, there are no vaccines approved for the prevention of HIV infection, but there are many clinical trials taking place that are studying experimental HIV vaccines. The purpose of this study is to evaluate the safety and tolerability of three different HIV vaccine schedules in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama CRS, Birmingham, Alabama +7 locations
Conditions: HIV Infections
Register for Updates
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
NCT01492582
Completed
This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2) determining the immune response to and safety/tolerability of the quadrivalent and nonavalent HPV vaccine in young cancer survivors.
Gender:
ALL
Ages:
Between 9 years and 26 years
Trial Updated:
10/07/2021
Locations: University of Alabama at Birmingham, Birmingham, Alabama +4 locations
Conditions: Cancer Survivor, Prevention of Human Papillomavirus Infection
Register for Updates
Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer
NCT02018458
Completed
The primary objective of this study is to determine the safety and feasibility of combining cyclin B1/WT-1/CEF (antigen)-loaded DC vaccination with preoperative chemotherapy. The secondary objectives of this trial are to determine pathologic complete response rates; disease-free survival; to assess immune biomarkers of immunity (antigen-specific CD8+ T cell immunity and TH2 T cells) in breast cancer biopsy specimens and blood samples in patients receiving DC vaccinations; and to assess the feas... Read More
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
10/07/2021
Locations: Baylor University Medical Center, Dallas, Texas
Conditions: Breast Cancer
Register for Updates
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants
NCT02927873
Completed
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of the respiratory syncytial virus (RSV) candidate vaccine when first administered via intramuscular (IM) injection according to a 0, 1-month schedule to RSV-seropositive infants aged 12 to 23 months.
Gender:
ALL
Ages:
Between 12 months and 23 months
Trial Updated:
09/28/2021
Locations: GSK Investigational Site, Anaheim, California +23 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
The Impact of Vaccination on Severity of Illness in COVID-19
NCT04912700
Completed
With the FDA's emergency use authorization declaration in December of 2020, the Pfizer-BioNtech vaccine became the first of several vaccines to kick off the mass vaccination effort across the United States against CoronaVIrus Disease 2019 (COVID-19). Subsequently, Moderna as well as Johnson and Johnson both had vaccines receive emergency use authorization. While the Pfizer and the Moderna vaccines both utilize novel mRNA technology, Johnson and Johnson's vaccine uses a viral vector that has been... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2021
Locations: Beaumont Hospital - Royal Oak, Royal Oak, Michigan
Conditions: Covid19
Register for Updates
H3N2 M2SR in Pediatric Population
NCT03553940
Completed
This is a Phase I double-blind, randomized, placebo-controlled study in 50 healthy adolescents and children, 9-17 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety and immunogenicity of a prime-boost regimen of H3N2 M2SR intranasal influenza vaccine (manufactured by FluGen) followed by licensed inactivated Quadrivalent Influenza Vaccine (QIV) boost administered intramuscularly Subjects will be enrolled in one o... Read More
Gender:
ALL
Ages:
Between 9 years and 17 years
Trial Updated:
09/23/2021
Locations: Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri
Conditions: Influenza, Influenza Immunisation
Register for Updates
Immunologic Response to FluMist vs. Flucelvax
NCT03982069
Completed
The purpose of this study is to evaluate immunologic response to different types of influenza vaccine among children/adolescents/young adults 4-21 years of age. This is a randomized controlled trial (RCT), that will assess immune response in about 440 participants (about 220 per vaccine arm) pre- and post-vaccination to FluMist (live attenuated influenza vaccine given by nasal administration) and Flucelvax (egg-free cell-culture inactivated influenza vaccine).
Gender:
ALL
Ages:
Between 4 years and 21 years
Trial Updated:
09/17/2021
Locations: General Academic Pediatrics, Pittsburgh, Pennsylvania +1 locations
Conditions: Influenza, Human, Immune Response
Register for Updates